Supratentorial glioblastoma in adults: Identification of subsets and their clinical correlation

Brain Tumor Pathology

Volumn 21, Issue 1, 2004, Pages 7-12

  Sarkar, Chitra ^a   Sinha, Subrata ^a   Sharma, Mehar Chand ^a   Kumar, Rajender ^a   Mehta, Veer Singh ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Adult; Age; EGFR; GBM; p53; Subsets; Supratentorial; Survival

Indexed keywords

BIOCHEMICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P53;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BRAIN TUMOR; CANCER GRADING; CANCER SURVIVAL; FEMALE; GENETIC VARIABILITY; GLIOBLASTOMA; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN EXPRESSION; TUMOR GROWTH;

ADULT; AGE FACTORS; AGED; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; SUPRATENTORIAL NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 3142779911     PISSN: 14337398     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02482170     Document Type: Article

References (35)

1. Kleihues P, Burger PC, Collins VP, et al (2000) Glioblastoma. In: Kleihues P, Cavenee WK (eds) Pathology and genetics of tumors of the nervous system. WHO classification of tumors. International Agency for Research on Cancer, Lyon, pp 29-39
2. Newcomb EW, Cohen H, Lee SR, et al (1998) Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes. Brain Pathol 8:655-667
3. Lang FF, Miller DC, Koslow M, et al (1994) Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. J Neurosurg 81:427-436
4. Ohgaki H, Schauble B, zur Hausen A, et al (1995) Genetic alterations associated with the evolution and progression of astrocytic brain tumours. Virchows Arch 427:113-118
5. Hayashi Y, Ueki K, Waha A, et al (1997) Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme. Brain Pathol 7:871-875
6. von Deimling A, von Ammon K, Schoenfeld D, et al (1993) Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 3:19-26
7. van Meyel DJ, Amsay DA, Casson AG, et al (1994) p53 mutation, expression and DNA ploidy in evolving gliomas: evidence for two pathways of progression. J Natl Cancer Inst 86:1011-1017
8. Chozick BS, Weicker ME, Pezzullo JC, et al (1994) Pattern of mutant p53 expression in human astrocytomas suggests the existence of alternate pathways of tumorigenesis. Cancer 73:406-415
9. Reifenberger J, Ring GU, Gies U, et al (1996) Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. J Neuropathol Exp Neurol 7:822-831
10. von Deimling A, Louis DN, Weistler OD (1995) Molecular pathways in formation of gliomas. Glia 15:328-338
11. Watanabe K, Tachibana O, Sato K, et al (1997) Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6:217-224
12. Louis DN (1997) A molecular genetic model of astrocytoma histopathology. Brain Pathol 7:755-764
13. Kleihues P, Ohgaki H (1997) Genetics of glioma progression and the distribution of primary and secondary glioblastomas. Brain Pathol 7:1131-1136
14. Louis DN, Gusella JF (1995) A tiger behind many doors: multiple genetic pathways to malignant gliomas. Trends Genet 11:412-415
15. Sung T, Miller DC, Hayes RL (2000) Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas. Brain Pathol 10:249-259
16. Chen Y, Ng H-K, Zhang S-F, et al (1999) Genetic alterations in pediatric high-grade astrocytomas. Hum Pathol 30:1284-1290
17. Litofsky NS, Hinton D, Raffel C (1994) The lack of role of p53 in astrocytomas in paediatric patients. Neurosurgery 34:967-973
18. Orellana C, Hernandez-Marti M, Marinez F, et al (1998) Paediatric brain tumors: loss of heterozygosity at 17p and TP53 gene mutations. Cancer Genet Cytogenet 102:93-99
19. Pollack IF, Hamilton RL, Finkelstein SD, et al (1997) The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood. Cancer Res 57:304-309
20. Sure U, Ruedi D, Tachibana O, et al (1997) Determinatio of p53 mutations, EGFR expression and loss of p16 expression in paediatric GBM. J Neuropathol Exp Neurol 56:782-789
21. Cavenee WK, Furnari FB, Nagana M, et al (2000) Diffusely infiltrating astrocytomas. In: Kleihues P, Cavenee WK (eds) Pathology and genetics of tumors of the nervous system. WHO classification of tumors. International Agency for Research on Cancer, Lyon, pp 10-21
22. Kleihues P, Ohgaki H (1998) Subsets of glioblastoma: clinical and histological vs. genetic typing. Brain Pathol 18:667-668 (editorial)
23. Rasheed BK, McLendon RE, Herndon JE, et al (1994) Alterations of the TP53 gene in human gliomas. Cancer Res 54:1324-1230
24. Tohma Y, Gratas C, Biernat W, et al (1998) PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J Neuropathol Exp Neurol 57:684-689
25. Wong AJ, Bigner SH, Bigner DD, et al (1987) Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA 84:6899-6903
26. Louis DN (1994) The p53 gene and protein in human brain tumors. J Neuropathol Exp Neurol 53:11-21
27. Louis DN, von Deimling A, Chung RY, et al (1993) Comparative study of p53 gene and protein alterations in human astrocytic tumors. J Neuropathol Exp Neurol 52:31-38
28. Newcomb EW, Madonia WJ, Pisharody S, et al (1993) A correlative study of p53 protein alteration and p53 gene mutation in glioblastoma multiforme. Brain Pathol 3:229-235
29. Sarkar C, Rathore A, Chattopadhyay P, et al (2000) Role of 17p13.3 chromosomal region in determining p53 protein immunopositivity in human astrocytic tumors. Pathology 32:84-88
30. Chattopadhyay P, Rathore A, Mathur M, et al (1997) Loss of heterozygosity of a locus on 17p13.3, independent of p53, is associated with higher grades of astrocytic tumours. Oncogene 15:871-874
31. Sarkar C, Ralte AM, Sharma MC, et al (2002) Recurrent astrocytic tumors - a study of p53 immunoreactivity and malignant progression. Br J Neurosurg 16:335-342
32. Dropcho EJ, Soong SJ (1996) The prognostic impact of prior low grade histology in patients with anaplastic gliomas: a case control study. Neurology 47:684-690
33. Wales MM, Biel MA, el Deiry W, et al (1995) p53 activates expression of HIC-1, a new candidate tumor suppressor gene in 17p13.3. Nat Med 1:570-571
34. Schulz D, Vanderveer L, Berman DB, et al (1996) Identification of two candidate tumor suppressor genes in chromosome 17p13.3. Cancer Res 56:1997-2002
35. Sarkar C, Chattopadhyay P, Ralte AM, et al (2003) Loss of heterozygosity of a locus in the chromosomal region 17p13.3 is associated with increased cell proliferation in astrocytic tumors. Cancer Genet Cytogenet 15:156-164